We’re probably going to see an increasing number of of reports like Genetic Drivers of Immune Response to Cancer Discovered Through ‘Big Data’ Analysis where access to and analysis of a large body of previously collected data leads to significant findings.
I’m currently migrating this web site to the more mobile friendly Squarespace 7 platform located here.
Entries in Project Management (152)
Whatever the environment, new data management and analysis technology may be important, but success and sustainability will also be driven by how we manage it and by how successful we are in putting data users and their priorities into the driver’s seat.
As an extension of my own research and consulting on big data project planning and management, I wanted to improve my understanding of how data governance and program management practices impact how medical and health data are used.
I’m fairly “old-school” when it comes to planning and building information systems. That is, first you decide what your requirements are and what services you need to provide, then you decide which technologies you need to adapt, develop, or purchase to help you meet those requirements.
Government regulators need to be sensitive to the costs of complying with and overseeing the regulations they impose on data management, as do the organizations that are regulated. Costs related to data oversight, quality control, standardization, security, and privacy all need to be considered in comparison with the quantitative and qualitative benefits that will be generated.
If you’re doing exploratory data analysis to help you decide how much data prep might be needed to make your data public, that’s one thing. On the other hand, if you are using your data to calculate input to an invoicing system, that’s another.
Given the wide variations that currently exist in most organizations in understanding the ins and outs of managing current data governance and analytics practices, it’s not surprising that bringing in potentially “disruptive” technologies will be even more of a challenge.
To appreciate some of the implications of the recent proposal by the International Committee of Medical Journal Editors (ICMJE) to make consideration of journal article acceptance contingent upon the author’s agreement to share de-identified clinical trial data with other researchers, as reported by NPR, some context is appropriate.
A good place to start will be to get a good handle on the costs and benefits of introducing new big data related initiatives into the organization; the more realistic these costs and benefits, are the better.
There’s a lot more to collaboration than just providing a technology platform.